drugset / Trial / NCT02913326

A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis (RE-SPECT CVT)

NCT02913326

Phase 3 Completed 120 enrolled Boehringer Ingelheim
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a multi-center, prospective, international, randomized (1:1), open-label study with two parallel groups. This phase III study is planned to investigate the efficacy and safety of dabigatran etexilate versus dose-adjusted warfarin on a net clinical benefit endpoint of major bleeding (ISTH criteria) and new venous thrombotic event (VTE) (primary endpoint) with blinded endpoint adjudication.

Timeline

Start
2016-12-13
Primary completion
2018-06-22
Completion
2018-06-22

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabigatran etexilate Unknown 150 mg Oral
Comparator Warfarin Small molecule Oral